 |
|
Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In their Research Letter, Dr Opotowsky and colleagues1 reported an increase in percutaneous closure of interatrial defects. There are a number of points that we believe need to be considered in interpreting the data presented in their article.
Patent foramen ovale (PFO) and atrial septal defect (ASD) were classified together in the analysis, so specific comment on the indication for closure should be cautious. In addition, the observation that the rate of interatrial shunt closure has increased disproportionate to coronary revascularization following the introduction of stents needs to be viewed in context. This is due in part to far fewer PFO/ASD closures being performed in comparison with coronary revascularization at the commencement of the relevant periods. This increase is also likely to be magnified by significant improvements in equipment, devices, operator training, and lesion identification.
With regard to PFO closure, the US Food and Drug Administration (FDA) . . . [Full Text of this Article]
Ravinay Bhindi, MBBS, PhD
ravinay.bhindi@cardiov.ox.ac.uk
Oliver J. Ormerod, DM, FRCP
Department of Cardiology
John Radcliffe Hospital
Oxford, England
RELATED ARTICLE
Trends in the Use of Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect in Adults, 1998-2004
Alexander R. Opotowsky, Michael J. Landzberg, Stephen E. Kimmel, and Gary D. Webb
JAMA. 2008;299(5):521-522.
EXTRACT
| FULL TEXT
RELATED LETTER
Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect—Reply
Alexander R. Opotowsky, Michael J. Landzberg, and Gary D. Webb
JAMA. 2008;299(19):2272-2273.
EXTRACT
| FULL TEXT
|
